Çanakkale onsekiz mart üniversitesi hematoloji bilim dalına başvuran hematolojik maligniteli hastaların retrospektif olarak değerlendirilmesi

Year 2023, , 49 - 54, 31.05.2023

Burak Tok , Celal Acar

https://doi.org/10.55665/troiamedj.1229528

Abstract

Amaç: Çalışmamızda; hastanemize başvuran hematolojik maligniteli hastaların sıklığının cinsiyet, yaş ve tanıya göre dağılımının saptanması, hastalara eşlik eden kronik hastalıkların, hastaların yaşam sürelerinin ve hayatta kalma durumlarının belirlenmesi amaçlandı.
Yöntem: Çanakkale Onsekiz Mart Üniversitesi Uygulama ve Araştırma Hastanesi Hematoloji Bölümü’ne Mart 2019-Temmuz 2020 tarihleri arasında başvuran veya burada tanı konulan hematolojik maligniteli hastalar retrospektif olarak incelenmiştir.
Bulgular: Çalışmamızda hematolojik maligniteli toplam 411 olgunun 191 tanesi (%46) kadın, 220 tanesi (%54) erkek olarak saptanmıştır. Toplamda ölüm oranı %11.7’dir. Hematolojik maligniteli olguların %1’ini ALL, %4’ünü AML, %4’ünü HL, %21’ini NHL, %18’ini plazma hücre diskrazisi, %7’sini MDS ve %33’ünü kronik miyeloproliferatif hastalıklar oluşturmaktadır. En sık NHL alt tipi DBBHL iken en sık KMPH alt tipi ise esansiyel trombositoz olarak saptandı. Hematolojik malignitelere en sık eşlik eden kronik hastalığın ise hipertansiyon olduğu görüldü.
Sonuç: Mevcut bilgilerimize göre ülkemizde ve bölgemizde hematolojik maligniteler konusunda düzenli istatistiksel veriler bulunmamaktadır. Biz bu çalışmada; Çanakkale ve yakın çevresindeki hematolojik hastalıkların sıklığını hesaplamayı ve bu verilerin literatür ile uyumlu olup olmadığını saptamayı hedefledik.

Keywords

Hematolojik malignite, retrospektif çalışma, kronik hastalık, istatistik

Retrospective evaluation of patients with hematological malignancies admitted to çanakkale onsekiz mart university hematology department

Abstract

Objectives: In our study; It was aimed to determine the frequency of hematological malignancies who admitted to our hospital for diagnosis, treatment or follow-up according to gender, age and diagnosis, and to determine the chronic diseases accompanying patients, the survival and survival status of the patients.
Methods: Patients with hematological malignancies who admitted to Çanakkale Onsekiz Mart University Application and Research Hospital Hematology Department between March 2019-July 2020, or were diagnosed there were retrospectively analyzed.
Results: In our study, 191 (46%) of 411 patients with hematological malignancies were found female and 220 (54%) male. Overall, the death rate is 11.7%. Of the hematological malignancies, 1% consists of ALL, 4% AML, 4%, HL, 21% NHL, 18% plasma cell dyscrasia, 7% MDS and 33% chronic myeloproliferative diseases. While the most common NHL subtype was DBBHL, the most common KMPH subtype was found essential thrombocytosis. It was observed that the most common chronic disease a companying hematological malignancies was hypertension.
Conclusion: According to our current knowledge, there are no regular statistical data on hematological malignancies in our country and in our region. In this study. We aimed to calculate the frequency of hematological diseases in Çanakkale and its surroundings and to determine whether these data are compatible with the literature.

Keywords

Hematological malignancy, retrospective study, chronic disease, statistics

References

• 1.Tumors of the hematopoietic and lymphoid tissues https://en.wikipedia.org /wiki/ Tumors of the hematopoietic and lymphoid tissues. (erişim tarihi: 20.09.2020)
• 2.nationalfoundation for cancer https://www.nfcr.org/blog/7-facts-need-know-blood-cancers/ (erişim tarihi: 15.03.2021)
• 3. Li SY, Ye JY, Meng FY et al. Clinical characteristics of acute lymphoblastic leukemia in male and female patients: A retrospective analysis of 705 patients. OncolLett. 2015 Jul;10(1):453-458
• 4. Gbadamosi B, Ezekwudo D, Bastola S. Et al. Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single-Institution Experience. Clin Lymphoma MyelomaLeuk. 2018Jul;18(7):e287-e294. doi:10.1016/j.clml.2018.05. 005.
• 5. Leukemia - Chronic Lymphocytic - CLL: Statistics. https://www.cancer.net/cancer-types/leukemia-chronic lymphocyticcll/ statistics. (erişim tarihi: 15.04.2021)
• 6. Kabadi SM, Kumar SR, Wong JL. Retrospective Elect-ronic Medical Records Study of Treatment Patterns Among CLL Patients in the Cancer LinQ Research Database. Blood 2019; 134 (Supplement_1): 5810.
• 7. Ünal A. .Hodgkin Lenfoma Türk Hematoloji Derneği Klinisyen-Patolog Ortak Lenfoma Kursu. 2004 Mart: 101-116
• 8. Key Statistics for Hodgkin Lymphoma- American Cancer Society,https://www.cancer.org/cancer/hodgkin-lymphoma/about/key-statistics.html (erişim tarihi: 24.03. 2023)
• 9. Thandra KC, Barsouk A, Saginala K. Epidemiology of Non-Hodgkin’s Lymphoma Med Sci (Basel). 2021 Mar; 9(1): 5.doi: 10.3390/medsci9010005
• 10. Liu W, Ji X, Song Y, et al. Improvingsurvival of 3760 patientswithlymphoma: Experience of an academiccenterovertwodecades. CancerMed. 2020; 9: 3765– 3774
• 11. Sağlam A, Esin E, Hayran M. ve ark. Distribution of lymphomas in Turkey: data of 4239 casesfrom a single institution using the WHO classification. Turk J MedSci.2018 Oct 31;48(5):1013-1023
• 12. Siegel RL, Miller KD, Fuchs HE. Et al. Cancer Statis-tics, 2021 CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322 /caac.21654. 13. Blimark CH, Turesson I, Genell A. et al. Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry. Haematologica 2018 Volume 103(3):506-513 doi:10.3324/ haematol.2017.178103.
• 14. Castillo JJ, Mull N, Regan JL. et al. İncreased incidance of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2:A meta-analysis of observational studies. Blood. 2012;119:4845-4850. DOI:10.1182/Blood-2011-06-362830
• 15. Ma X, Epidemiology of Myelodysplastic Syndromes Am J Med. 2012 Jul; 125(7 Suppl): S2–S5. doi: 10.1016/j.amjmed.2012.04.014
• 16. Shallis R.M, Wang R, Davidoff A, et al. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. Blood Rev. 2020;42:100706.
• 17. Leukemia and Lymphoma Society, Polycythemia Vera Facts, FS13, revised April 2015.https://www.lls.org/sites/default/files/file_assets/FS13_PolycythemiaVera_FactSheet_final5.1.15.pdf (erişim tarihi: 30.03.2021)
• 18. Ashorobi D, Gohari P. Essential Thrombocytosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. (erişim tarihi:23.03.2023)
• 19. Leukemia - Chronic Myeloid - CML: Statistics. https://www.cancer.net/cancer types /leukemia chronicmyeloidcml /statistics. (erişim tarihi: 07.03.2021)
• 20. Myelofibrosis Epidemiology - Rare Disease Advisor https://www.raredisease advisor.com/disease-info-pages/myelofibrosis-epidemiology/ (erişim tarihi:25.03. 2023)